References
- Ambudkar SV, Dey S, Hrycyna CA, et al (1999). Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol, 39, 361-98. https://doi.org/10.1146/annurev.pharmtox.39.1.361
- Borst P, Evers R, Kool M, Wijnholds JJ (2000). Title??? J Natl Cancer Inst, 92, 1295-302. https://doi.org/10.1093/jnci/92.16.1295
- Bunting KD (2002). ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells, 20, 11-20. https://doi.org/10.1002/stem.200011
- Cole SPC, Bhardwaj G, Gerlach JH, et al (1992). Overexpression of a novel transporter gene in a multidrug resistant human lung cancer cell line. Science, 258, 1650.
- Cole SP, Bhardwaj G, Gerlach JH, et al (1992). Science, 258, 1650-4. https://doi.org/10.1126/science.1360704
- Endicott JA, Ling V (1989).Title??? Annu Rev Biochem, 58, 137-71. https://doi.org/10.1146/annurev.bi.58.070189.001033
- Fardel O Lecureur V, Guillouzo A (1996). The P-glycoprotein multidrug transporter. Gen Pharmacol, 27, 1283-91. https://doi.org/10.1016/S0306-3623(96)00081-X
- Gottesman MM, Fojo T, Bates SE (2002). Multidrug resistance in cancer, role of ATP-dependent transporters. Nat Rev Cancer, 2, 48-58. https://doi.org/10.1038/nrc706
- Gottesman MM, Hrycyna CA, Schoenlein PV (1995). Genetic analysis of the multidrug transport. Annu Rev Genel, 29, 607-49. https://doi.org/10.1146/annurev.ge.29.120195.003135
- Gottesman MM, Licht T, Zhou Y, et al (2000). Selectable markers for gene therapy. In Gene Therapy: Therapeutic Mechanisms and Strategies, ed. D Lasic, N Templeton, 16, 333-52.
- Gottesman MM, Pastan I (1993). Title??? Annu Rev Biochem, 62, 385-427. https://doi.org/10.1146/annurev.bi.62.070193.002125
- Gottesman MM, Fojo T, Bates SE (2002).Title??? Nat Rev Cancer, 2, 48-58. https://doi.org/10.1038/nrc706
- Higgins CF (1992).Title??? Ann Rev Cell Biol, 8, 67-113. https://doi.org/10.1146/annurev.cb.08.110192.000435
- Hipfner DR, Deeley RG, Cole SP (1999). Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta, 1461, 359-76. https://doi.org/10.1016/S0005-2736(99)00168-6
- Holleman A, Cheok MH, Den Boer ML, et al (2004). Gene expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med, 351, 533-42. https://doi.org/10.1056/NEJMoa033513
- Jean-Pierre Marie, Olliver LeGrand (2003). Drug resistance in acute leukaemia and reversion. Turk J Med Sci, 33, 271-9.
- Klein I, Sarkadi B, Varadi A (1999). Biochim Biophys Acta, 1461, 237-62. https://doi.org/10.1016/S0005-2736(99)00161-3
- Kool M, De Haas M, Scheffer GL, et al (1997). Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologs of the multidrug resistance-associated protein gene (MRP1), in human cancer cell line. Cancer Res, 57, 3537.
- Kool M, Van Der Linden M, De Haas M, Baas F, Borst P (1999). Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res, 59, 175.
- Krishna R, Mayer LD (2000). Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci, 11, 265-83. https://doi.org/10.1016/S0928-0987(00)00114-7
- Leslie EM, Deeley RG, Cole SP (2001). Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology, 167, 3-23. https://doi.org/10.1016/S0300-483X(01)00454-1
- Mitelman F (1991 ). ISCN Guidelines for Cancer Cytogenetics: Supplement to an International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger.
- Plasschaert SL, Vellenga E, De Bont ES, et al (2003). High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children. Leuk Lymphoma, 44, 85-95. https://doi.org/10.1080/1042819021000040288
- Ros JE, Libbrecht L, Geuken M, Jansen PL, Roskams TA (2003). High expression of MDR1, MRP1and MRP3 in the hepatic progenitor cell compartment and hepatocytes in several human liver disease. J Pathol, 200, 553-60. https://doi.org/10.1002/path.1379
- Sabine L, Plasschaert A, Eveline SJM (2005). Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res, 11, 24.
- Sauerbrey A, Voigt A, Writtig S, Hafer R, Zintl F (2002). Messenger RNA analysis of the multidrug resistance related protein (MRP1) and the lung resistance protein (LRP) in de novo and relapsed childhood acute lymphoblastic leukemia. Leuk Lymphoma, 43, 875-9. https://doi.org/10.1080/10428190290017024
- Simon M, Schindler M (1994). Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA, 91, 3497. https://doi.org/10.1073/pnas.91.9.3497
- Sonneveid P (2000). Multidrug resistance in haematological malignancies. J Intern Med, 247, 521-34. https://doi.org/10.1046/j.1365-2796.2000.t01-1-00689.x
- Strautnieks SS, Bull LN, Knisely AS (1998). Nat Genet, 20, 233-8. https://doi.org/10.1038/3034
- Taniguchi K, Wada M, Kohno K, et al (1996). A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res, 56, 4124.
- Thomas R (2000). Chemotherapy resistance in acute leukemia. Turk J Haematol, 17, 155-162.
- Ueda K, Taguchi Y, Morishima M (1997).Title??? Semin Cancer Biol, 8, 151-9. https://doi.org/10.1006/scbi.1997.0066
- Wijnholds J, Mol CA,Van Deemter L, et al (2000). Multidrug-resistance protein 5 is a multispecific organic an-ion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA, 97, 7476-81. https://doi.org/10.1073/pnas.120159197
- Wijnholds J, Mol CA, Van Deemter L, et al (2003). Multidrugresistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA, 97, 7476-81.
- Yoshida M, Suzuki T, Komiva T, et al (2001). Induction of MRP5 and SMRP mRNA by Adriamycin exposure and its overexpression in human lung cancer cells resistant to Adriamycin. Int J Cancer, 94, 432-7. https://doi.org/10.1002/ijc.1490
Cited by
- Reversal of Resistance towards Cisplatin by Curcumin in Cervical Cancer Cells vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1403
- RNAi-based Knockdown of Multidrug Resistance-associated Protein 1 is Sufficient to Reverse Multidrug Resistance of Human Lung Cells vol.15, pp.24, 2014, https://doi.org/10.7314/APJCP.2014.15.24.10597
- High Expression of Lung Resistance Protein mRNA at Diagnosis Predicts Poor Early Response to Induction Chemotherapy in Childhood Acute Lymphoblastic Leukemia vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6663
- MRP1 and its role in anticancer drug resistance vol.47, pp.4, 2015, https://doi.org/10.3109/03602532.2015.1105253